Precise staging of the dissemination of the disease is critical in the treatment and prognosis of patients with Hodgkin's disease (HD). To determine the extent of the disease, several imaging techniques are currently employed, e.g. plain chest radiography, computed tomography (CT), sonography and lymphangiography (North & Jing, 1988) . These techniques are also used to assess the response of the disease at different sites to treatment. Gallium scintigraphy is variably used in the work-up of patients with HD (Front et al, 1995) .
A variety of human neoplasms express somatostatin receptors (SS-Rs). SS-Rs have been found in neuroendocrine (Reubi et al, 1987 (Reubi et al, , 1990a , breast (Reubi et al, 1990b; van Eijck et al, 1994 ) and brain tumours (Reubi et al, 1986) . In order to take advantage of SS-R tissue expression, radiolabelled somatostatin (SS) analogues have been applied to visualize SS-R-positive tumours in vivo with a gammacamera. SS-R scintigraphy has proved clinically useful for refined tumour localization in patients with carcinoid tumours, pancreatic endocrine tumours and paragangliomas (Krenning et al, 1989 (Krenning et al, , 1995 Lamberts et al, 1990; Kwekkeboom et al, 1993) .
SS-Rs are expressed on the membranes of human lymphoid cells, including malignant lymphoma and HD , as has become apparent from autoradiography of tissue sections. There is as yet only limited experience with SS-R scintigraphy in patients with HD (Bares et al, 1993; van Hagen et al, 1993; Bong et al, 1994; Lipp et al, 1995) . We set out to evaluate SS-R scintigraphy as a potentially useful method for in vivo imaging of tumour deposits in patients with HD. Here we present the results of a prospective study in 56 newly diagnosed, previously untreated, patients with histologically proven HD.
#
1996 Blackwell Science Ltd, British Journal of Haematology 93: [96] [97] [98] [99] [100] [101] [102] [103] established by conventional methods which included a physical examination, chest radiography, CT of chest, abdomen and pelvis, bone marrow biopsy, and occasionally lymphangiography. All patients had given informed consent to the study, which was approved by the ethics committee of the University Hospital Rotterdam.
Scintigraphy. SS-R scintigraphy was performed after intravenous injection of the radioactive labelled SS analogue [ ]octreotide, the dose administered (222 MBq) and the technique of scintigraphy with the gamma-camera, as well as with single photon emission computed tomography (SPECT) have recently been described (Bakker et al, 1991; Krenning et al, 1992 Krenning et al, , 1993 Krenning et al, , 1994 Krenning et al, , 1995 . Planar total body scintigraphy was performed 24 h post-injection with a largefield-view gamma camera (Counterbalance 3700 and ROTA II; Siemens Gammasonics, Erlangen, Germany) equipped with a medium-energy collimator. In all patients SPECT images of the upper abdomen were made. For both planar and SPECT scintigraphy, images with a long exposure time were obtained, e.g. 15 min for planar views. Repeat scintigraphy of the abdomen was performed 48 h post-injection when 24 h scintigraphy showed accumulation in the abdomen. In normal individuals a physiological accumulation of radioactivity may be seen at 24 h after intravenous administration of [ and may be reduced following the use of laxatives . The SS-R scans were evaluated by two investigators at the same time without knowing patient identity or results of the conventional diagnostic work-up. Finally, the results of the SS-R scans and conventional diagnostic tests were compared by the study coordinator. In case of discrepancies additional radiodiagnostic investigations were scheduled before the beginning of treatment and, if practically possible, cytological or histological verification was sought. In nine patients SS-R scintigraphy was repeated after therapy. All patients were followed during and after treatment.
Autoradiography. In three patients SS-R autoradiography was performed on 10 m thick cryostat sections of tumour samples, using a iodinated SS octapeptide analogue [ (Reubi et al, 1987 (Reubi et al, , 1990a .
RESULTS
The clinical characteristics of the 56 patients with HD in whom SS-R scintigraphy was performed are given in Table I. SS-R scintigraphy indicated SS-R positivity at areas of documented active disease in 55 cases (98%). Two examples of SS-R scintigraphy of lymphoma localizations above the diaphragm are shown in Fig 1A (mediastinum) and Fig 1B  (neck) . In Figs 2A-C a SS-R scintigram of multiple para-aortic abdominal lymph nodes is shown.
Additional sites of HD revealed by SS-R scintigraphy (20 patients)
In 20 patients SS-R scintigraphy disclosed activity suggestive of lymphoma which had not been revealed following physical and radiological examination. Table II (n 1), but also in the para-aortic region (n 5) and the inguinal area (n 2). In patient 10, following the results of SS-R scintigraphy, we confirmed the presence of an abnormal lymph node in the neck on repeated palpation (1 . 5 cm diameter). In the same patient multiple small intrapulmonal 'lesions' were seen on CT, which were read as possible Hodgkin localizations. The intrapulmonal lesions were negative on SS-R scintigraphy. After six cycles of chemotherapy no residual masses were seen. The radiographic intrapulmonalabnormalities that had been SS-R negative had not changed and were retrospectively interpreted as preexistent abnormalities of unclear nature (follow-up time 2 years). In the majority of patients additional investigations were performed to verify the diagnosis at discrepant sites (see Table II ). The superiority of SS-R scintigraphy was confirmed in 12/20 patients, i.e. by repeated palpation (n 4), subsequent radiodiagnostic tests (n 6) and/or cytopathology (n 2). In the latter 12 patients the physical and radiological abnormalities disappeared following cytotoxic treatment (Table II, follow-up) . In nine patients SS-R scintigraphy was repeated after successful chemotherapy and in all patients SS-R scintigraphy had become entirely negative (Table II, 
repeated SS-R scintigraphy).
In 12 patients the discrepancies between SS-R scintigraphy and conventional staging procedures resulted in a change of Ann Arbor clinical stage. SS-R scintigraphy findings correctly upgraded the clinical stage in 11 cases and the clinical stage was correctly downgraded in one patient. As a result the treatment plan was altered in seven patients. In all seven patients the superiorityof SS-R scintigraphy was supported by additional evidence.
False-negative results of SS-R scintigraphy (four patients)
In four patients SS-R scintigraphy did not show localizations which had become apparent following radiological methods (see Table III ). In patients 3, 7 and 26 enlarged abdominal para-aortic lymph nodes visualized on CT and lymphangiography were not apparent on SS-R scintigraphy images. The largest non-visualized lesion in the abdominal area had a diameter of 4 . 5 cm. In all three patients the enlarged para-aortic lymph nodes disappeared after treatment. In the fourth patient (40), SS-R scintigraphy demonstrated a normal-sized spleen with a homogenous distribution of radioactivity, but CT and sonography showed a spleen of normal size with multiple hypodense areas, which disappeared following chemotherapy. In these four patients in whom SS-R scintigraphy missed certain localizations of HD, the clinical stage, if based on SS-R scintigraphy only, would have been underestimated in one individual.
Spleen and abdominal lymph node involvement with HD
What about the performance of SS-R scintigraphy with regards to abdominal involvement with HD? The spleen was enlarged in seven patients according to CT and sonography. In five of these individuals multiple hypodense areas were also apparent (see Table IV ). In all seven patients SS-R scintigraphy showed an enlarged spleen with a homogenous distribution of radioactivity. In an eighth patient (no. 40), where CT and sonography showed multiple hypodense areas in a normal-sized spleen, the spleen appeared normal on SS-R scintigraphy. Therefore SS-R scintigraphy failed to demonstrate spleen involvement in one patient. Enlarged abdominal para-aortic lymph nodes were seen on CT and lymphangiography in eight patients, five of whom were also SS-R SS-R scintigraphy, somatostatin receptor scintigraphy; CSM, conventional staging methods. SS-R scintigraphy/CSM : abnormalities visualized by SS-R scintigraphy and CSM; SS-R scintigraphyÿ/ CSM : abnormalities visualized only by CSM; SS-R scintigraphy/ CSMÿ : abnormalities visualized only by SS-R scintigraphy. Numbers indicate patients with para-aortic or spleen abnormalities that were evident on SS-R scintigraphy and CSM. Table IV ). The smallest lymphoma within the abdomen demonstrated by SS-R scintigraphy had a diameter of approximately 2 . 0 cm. In five other patients para-aortic lymph nodes were visualized on SS-R scintigraphy that had not been detected on CT and lymphangiography. In three of these five patients the para-aortic SS-R-positive lesions disappeared after chemotherapy. In the other two patients SS-R scintigraphy was not repeated. One patient had enlarged parailiac lymph nodes on CT and these were also visualized by SS-R scintigraphy.
False-positive results of SS-R scintigraphy (three patients)
In three patients the positivity on SS-R scintigraphy on selected sites clearly was not related to localizations of HD (see Table V ). In two patients accumulation of radioactivity was observed in the nasal region. A sinusitis in one patient and a common cold in the other patient had caused the positive scan. The third patient showed abnormal accumulation of radioactivity in the anterior iliac spine after a bone marrow biopsy at that site.
Further results of SS-R scintigraphy and SS-R autoradiography
In 28/55 SS-R-positive patients the results of SS-R scintigraphy and conventional staging methods were concordant. The sites of disease and clinical stages are summarized in Table  VI . The smallest lymph node identified by SS-R scintigraphy located in the neck had a diameter of 1 . 0 cm. The only patient with an entirely negative SS-R scintigraphy had stage IVB HD with lymph nodes in the axilla and an infiltrated bone marrow.
Finally, side-effects were not noted in any of the patients following the administration of [ In three patients SS-R analysis was performed on surgically removed lymph nodes. Autoradiographic investigation confirmed the presence of specific SS-Rs in the tissue biopsies of malignant lymphoma in these individuals ( Figs 3A-C) . These lymph nodes were all positive in vivo on SS-R scintigraphy.
DISCUSSION
The accuracy of staging is a cornerstone of the treatment of patients with HD. Clearly, current staging is still highly inadequate. For instance, stage I and II patients considered at high risk of failure are frequently treated with systemic chemotherapy. For this purpose, in stages I and II, clinical prognostic factors are employed to select between locoregional or systemic therapy. Following treatment it may be difficult to distinguish between persisting active HD or fibrotic abnormalities, e.g. in case of residual radiological mediastinal masses still apparent following chemotherapy.
In the present study we employed SS-R scintigraphy in 56 consecutive patients with histologically proven HD. Among these, 98% of the patients showed a positive SS-R scan. SS-Rpositive localizations were apparent at different sites of active disease above and below the diaphragm. Since the pathophysiological basis of SS-R scintigraphy staging bears no relationship to that of the other diagnostic imaging techniques, SS-R scintigraphy appears to provide an independent approach to the evaluation of the dissemination of HD. Therefore SS-R scintigraphy may add essential information to the results of the complete staging process. The discrepancies between the results of SS-R scintigraphy and conventional staging work-up as reported here support this. In only 28 patients was complete concordance apparent between SS-R scintigraphy and physical examination, X-ray examination, CT scanning and lymphangiography.
Autoradiography demonstrated the presence of SS-Rs in the lymphoma tissues surgically removed from three patients with HD. [ ]octreotide (in presence of 10 ÿ 6 M of unlabelled [Tyr octreotide bind with high affinity and specificity to the same receptor (Bakker et al, 1991) . The identification of SS-Rs in vitro in biopsies from the lymph nodes with HD, confirms that the activity seen in vivo actually represented SS-Rpositive tumour tissue. In patients with histologically proven HD the tumours display SS-Rs of high enough affinity and density to apparently permit external imaging by the radiolabelled SS analogue in most cases. In 20 patients SS-R scintigraphy disclosed lesions not revealed following a variety of radiodiagnostic procedures. In most of these individuals additional investigations were undertaken in an effort to verify the diagnosis of HD at sites of discrepancy.
SS-R scintigraphy failed to demonstrate certain sites of HD in four cases and SS-R scintigraphy was entirely negative in one individual with extensive involvement of HD. In a significant proportion of cases the clinical stage as defined by conventional staging methods changed following consideration of the results of SS-R scintigraphy. In 11 cases of the entire series of 56 subjects the disease was upgraded to a higher stage. The additional information of SS-R scintigraphy resulted in a different choice of therapy in seven patients (13%).
As compared with conventional staging methods, SS-R imaging offers a number of distinct advantages. First, because the whole body is imaged, localizations in areas not under clinical suspicion can be evaluated, and therefore the full extent of the disease more accurately documented. Second, after treatment with chemo-or radiotherapy, residual or recurrent tumours of malignant lymphomas remain SS-R positive . SS-R scintigraphy may be potentially useful to assess remission and avoid 'over treatment' in patients in remission. SS-R scintigraphy may also be of use in the management of residual masses, including the notoriously difficult mediastinal localizations. Our preliminary experience in two patients with primary resistant HD gives some support that this may be true (data not shown). After six cycles of chemotherapy a residual mass was seen on CT in the mediastinum in one patient and in the para-aortic region of the abdomen in the second. SS-R scintigraphy was positive in these areas in both patients. Histologic confirmation of active HD at the latter sites was obtained in both patients. We are presently investigating the role of SS-R scintigraphy in the evaluation of treatment response in patients with HD in a prospective study.
In the abdominal region SS-R scintigraphy (unlike conventional techniques) revealed para-aortic lymph nodes in five patients. A repeated SS-R scintigraphy after chemotherapy in three of these patients showed total disappearance of the lesions. In 12 cases there was complete agreement between the results of SS-R scintigraphy and conventional radiodiagnostic techniques in the detection of abdominal sites of HD. SS-R scintigraphy failed to detect abdominal HD in four patients. Para-aortic lymph nodes were missed in three patients and spleen involvement was not apparent on SS-R scintigraphy in one patient. Thus, all false-negative cases of our series were located in the abdomen. This problem was also seen in patients with carcinoid tumours where planar images of SS-R scintigraphy failed to detect some liver metastases ]octreotide is rapidly cleared from the blood, predominantly excreted via the kidneys, and a minority of the isotope removed by hepatobiliary clearance . The hepatobiliary clearance results in hepatic and intestinal accumulation of radioactivity. The presence of intestinal radioactivity can usually be overcome by the use of laxatives. Nevertheless, in some patients radioactivity may remain in the colon and this may interfere with the detection of para-aortic lymph nodes. The physiological uptake of radioactivity in the liver, although less than in the spleen, may reduce optimal detection of liver involvement with SS-R-positive tumours. Overprojection of radioactivity of the liver, spleen and kidneys can hide positive lesions in lymph nodes on the planar images. The use of SPECT images of the upper abdomen in part may overcome this problem and is therefore recommended for the localization of abnormal lymph nodes in the spleen and liver hilar areas. The same is true for the para-aortic region of the upper abdomen.
SS-R scintigraphy is not specific for visualizing tissue involved with HD. Granulomatous diseases, autoimmune diseases and neuroendocrine tumours may result in positive SS-R scintigraphy images as well Vanhagen et al, 1994) . Obviously, therefore, SS-R scintigraphy cannot be used to diagnose malignant lymphoma. In this respect, SS-R scintigraphy shares the general limitations of most imaging techniques. In our study, three false-positive results were seen. In two cases the positivity in the nasal region on the scan was caused by an infection; clinically, these two patients had a common cold. This transient accumulation in the nasal region during the typical season of epidemic common cold/influenza is a well-known pitfall in the correct interpretation of SS-R scintigraphy . The third patient showed accumulation of radioactivity in the pelvis after bone marrow biopsy. Clinically a large haematoma was apparent. Our accumulated experience in more than a thousand patients has taught us that radioactivity may accumulate at sites of recent operation.
In several centres gallium scintigraphy is used in the workup of HD patients. Gallium scintigraphy is performed prior to therapy to provide information on the gallium avidity of the tumour at baseline. Current evidence would indicate that the sensitivity of gallium scintigraphy in the initial staging of patients with HD is in the order of 66-85% (Front et al, 1990; Hagemeister et al, 1990) . The most important value of gallium scintigraphy is therefore not in the initial staging of patients with HD but rather in the evaluation of lymphoma after treatment (Front et al, 1995) . It would be of interest to compare SS-R scintigraphy and gallium scintigraphy in the staging of HD in future studies. In this age of financial restraint these imaging techniques should be cost-effective. In Rotterdam a prospective cost-effective study is currently in progress that includes ultrasonography, computed tomography, galliumscintigraphy and SS-R scintigraphy.
In conclusion, SS-R scintigraphy provides a useful method of diagnostic evaluation of patients with HD. It is a relatively easy and harmless procedure. Obviously, further prospective studies in larger groups of patients, both pre-and posttreatment, will be needed to fully define its value and place in the management of patients with HD.
